A Single Arm Multi-center Study Investigating the at Home Administration of Trastuzumab Subcutaneous Vial for the Treatment of Patients With HER2-positive Early Breast Cancer

Trial Profile

A Single Arm Multi-center Study Investigating the at Home Administration of Trastuzumab Subcutaneous Vial for the Treatment of Patients With HER2-positive Early Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Trastuzumab (Primary) ; Trastuzumab
  • Indications Early breast cancer; Male breast cancer
  • Focus Adverse reactions; Registrational
  • Sponsors Roche
  • Most Recent Events

    • 11 Oct 2016 Interim safety results of this and other four phase 3 studies presented at the 41st European Society for Medical Oncology Congress (2016).
    • 02 Nov 2015 Planned End Date changed from 1 Aug 2017 to 1 Sep 2017 as per ClinicalTrials.gov record.
    • 02 Nov 2015 Planned primary completion date changed from 1 Aug 2017 to 1 Sep 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top